Loading stock data…
$3.60-0.70 (-16.28%)
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
AN2 Therapeutics, Inc. in the Healthcare sector is trading at $3.60 with a market capitalization of $212M. Wall Street consensus targets $9.00 (2 analysts), implying a +150.0% move over the next 12 months. The stock is currently 50% below its 52-week high of $7.19, remaining 7.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.90M↑ | -$10.55M↓ | -$9.32M↑ | -$10.04M↓ | -$7.22M |
| Net Income | -$8.19M↑ | -$10.03M↓ | -$8.71M↑ | -$9.35M↓ | -$6.46M |
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for pa...